AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 153 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,549 | +17.0% | 103 | +33.8% | 0.00% | – |
| Q2 2023 | $2,179 | +23.3% | 77 | 0.0% | 0.00% | – |
| Q1 2023 | $1,767 | -80.9% | 77 | -76.5% | 0.00% | – |
| Q4 2022 | $9,264 | +15.8% | 327 | +14.3% | 0.00% | – |
| Q3 2022 | $8,000 | +166.7% | 286 | +130.6% | 0.00% | – |
| Q2 2022 | $3,000 | -78.6% | 124 | -73.5% | 0.00% | – |
| Q1 2022 | $14,000 | -30.0% | 468 | -20.0% | 0.00% | – |
| Q4 2021 | $20,000 | -48.7% | 585 | -30.9% | 0.00% | – |
| Q3 2021 | $39,000 | -53.6% | 846 | -44.5% | 0.00% | – |
| Q2 2021 | $84,000 | +20.0% | 1,525 | +13.6% | 0.00% | – |
| Q1 2021 | $70,000 | +18.6% | 1,343 | -4.1% | 0.00% | – |
| Q4 2020 | $59,000 | +40.5% | 1,401 | +18.4% | 0.00% | – |
| Q3 2020 | $42,000 | -38.2% | 1,183 | -6.6% | 0.00% | – |
| Q2 2020 | $68,000 | +655.6% | 1,267 | +427.9% | 0.00% | – |
| Q1 2020 | $9,000 | – | 240 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rock Springs Capital Management LP | 2,661,605 | $61,137,067 | 1.46% |
| Bellevue Group AG | 4,013,500 | $92,190,095 | 1.34% |
| Eagle Health Investments LP | 267,630 | $6,147,461 | 1.20% |
| ARMISTICE CAPITAL, LLC | 3,460,000 | $79,476,200 | 1.14% |
| Integral Health Asset Management, LLC | 213,000 | $4,892,610 | 0.99% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 454,000 | $10,428,380 | 0.44% |
| ArrowMark Colorado Holdings LLC | 1,557,705 | $35,780,484 | 0.41% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,092,829 | $48,072,282 | 0.27% |
| Virtus ETF Advisers LLC | 9,932 | $228,138 | 0.13% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 614,533 | $14,115,823 | 0.09% |